Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

被引：0
|
作者：
Jeroen P. Jansen
Sabine Gaugris
Ernest H. Choy
Andrew Ostor
Julian T. Nash
Wiro Stam
机构：
[1] Mapi Values,Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology
[2] Outcome Research,Department of Rheumatology
[3] Merck & Co.,Department of Rheumatology, Royal National Orthopaedic Hospital
[4] Inc.,undefined
[5] GKT School of Medicine,undefined
[6] King’s College Hospital,undefined
[7] Addenbrooke’s Hospital,undefined
[8] Stanmore Hospital,undefined
[9] Mapi Values,undefined
来源：
PharmacoEconomics | 2010年 / 28卷
关键词：
Ankylose Spondylitis; Celecoxib; Naproxen; Etoricoxib; Bath Ankylose Spondylitis Disease Activity Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the cost effectiveness of etoricoxib (90mg/day) relative to celecoxib (200 or 400mg/day), and the non-selective NSAIDs naproxen (1000mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing spondylitis (AS) from the UK NHS perspective.
引用
收藏
页码：323 / 344
页数：21
相关论文
共 42 条
  • [1] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK
    Jansen, Jeroen P.
    Pellissier, James
    Choy, Ernest H.
    Ostor, Andrew
    Nash, Julian T.
    Bacon, Paul
    Hunsche, Elke
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3069 - 3078
  • [2] Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
    Andrew Moore
    Ceri Phillips
    Elke Hunsche
    James Pellissier
    Simone Crespi
    PharmacoEconomics, 2004, 22 : 643 - 660
  • [3] Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs?
    Gratacos, J.
    Moreno Martinez-Losa, M.
    Font, P.
    Montilia, C.
    Fernandez-Espartero, C.
    Linares, L. F.
    Brito, E.
    Oliva, J. C.
    Collantes-Estevez, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (01) : 94 - 99
  • [4] The safety of celecoxib in ankylosing spondylitis treatment
    Poddubnyy, Denis A.
    Song, In-Ho
    Sieper, Joachim
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (04) : 401 - 409
  • [5] Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs
    Watson, DJ
    Bolognese, JA
    Yu, C
    Krupa, D
    Curtis, S
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) : 1899 - 1908
  • [6] Selective versus non-selective NSAIDs as prophylaxis for heterotopic ossification following hip arthroplasty: a meta-analysis
    Migliorini, Filippo
    Pintore, Andrea
    Baroncini, Alice
    Pastor, Torsten
    Hildebrand, Frank
    Maffulli, Nicola
    JOURNAL OF ORTHOPAEDICS AND TRAUMATOLOGY, 2022, 23 (01)
  • [7] Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis
    Cryer, B.
    Luo, X.
    Assaf, A. R.
    Sands, G.
    Mardekian, J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 295 - 302
  • [8] The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis
    Ramey, DR
    Douglas, DJ
    Yu, C
    Bolognese, JA
    Curtis, SP
    Reicin, AS
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (05) : 715 - 722
  • [9] Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials
    Essex, Margaret Noyes
    Zhang, Richard Y.
    Berger, Manuela F.
    Upadhyay, Sameer
    Park, Peter W.
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (04) : 465 - 477
  • [10] Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients
    Walker, Chris
    Essex, Margaret N.
    Li, Chunming
    Park, Peter W.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2016, 44 (03) : 483 - 495
12345